Seven Fleet Capital Management LP Buys New Stake in Maze Therapeutics, Inc. $MAZE

Seven Fleet Capital Management LP purchased a new position in shares of Maze Therapeutics, Inc. (NASDAQ:MAZE) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 30,707 shares of the company’s stock, valued at approximately $917,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Royal Bank of Canada increased its holdings in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after buying an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Maze Therapeutics in the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. boosted its stake in shares of Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after acquiring an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Maze Therapeutics during the 4th quarter worth about $43,000. Finally, Russell Investments Group Ltd. grew its position in shares of Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares during the period.

Maze Therapeutics Stock Performance

NASDAQ:MAZE opened at $26.92 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 17.88 and a current ratio of 17.88. The stock has a market capitalization of $1.49 billion, a PE ratio of -10.64 and a beta of 2.14. Maze Therapeutics, Inc. has a fifty-two week low of $12.81 and a fifty-two week high of $53.65. The company has a fifty day moving average of $27.36 and a two-hundred day moving average of $34.05.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Tuesday, May 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). The firm had revenue of $20.00 million for the quarter. As a group, research analysts forecast that Maze Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jason V. Coloma sold 34,501 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total value of $1,034,339.98. Following the transaction, the chief executive officer directly owned 23,337 shares of the company’s stock, valued at approximately $699,643.26. This trade represents a 59.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Harold Bernstein sold 15,000 shares of Maze Therapeutics stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $26.22, for a total value of $393,300.00. Following the completion of the sale, the chief marketing officer owned 15,000 shares in the company, valued at approximately $393,300. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 141,470 shares of company stock worth $3,902,714 in the last 90 days. Insiders own 5.30% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on MAZE. Weiss Ratings restated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Truist Financial dropped their price objective on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a report on Tuesday, April 14th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $66.00.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.